ASKA Pharmaceutical Holdings Co (TSE:4886) LT-Debt-to-Total-Asset: 0.07 (As of Mar. 2026)

What is ASKA Pharmaceutical Holdings Co LT-Debt-to-Total-Asset?

ASKA Pharmaceutical Holdings Co TSE:4886 -1.27% 61 LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus rates TSE:4886 with a GF Score™ of 61/100 and a GF Value™ of 円2,400.87 (Fairly Valued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ASKA Pharmaceutical Holdings Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.07.

ASKA Pharmaceutical Holdings Co's long-term debt to total assets ratio increased from Mar. 2025 (0.06) to Mar. 2026 (0.07). It may suggest that ASKA Pharmaceutical Holdings Co is progressively becoming more dependent on debt to grow their business.

ASKA Pharmaceutical Holdings Co (TSE:4886) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ASKA Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Related Terms

ASKA Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for ASKA Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Chart

ASKA Pharmaceutical Holdings Co Annual Data

Trend

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

0.15

0.11

0.05

0.06

0.07

ASKA Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.09	0.08	0.08	0.07

61GF Score

ASKA Pharmaceutical Holdings Co Ltd TSE:4886

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ASKA Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Calculation

ASKA Pharmaceutical Holdings Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	8165	/	112379
	=	0.07

ASKA Pharmaceutical Holdings Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	8165	/	112379
	=	0.07

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.07 mean?

ASKA Pharmaceutical Holdings Co (TSE:4886) has a LT-Debt-to-Total-Asset of 0.07 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ASKA Pharmaceutical Holdings Co and its competitors.

Is ASKA Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset too high?

ASKA Pharmaceutical Holdings Co's current LT-Debt-to-Total-Asset is 0.07. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does ASKA Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

ASKA Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset of 0.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. ASKA Pharmaceutical Holdings Co's current LT-Debt-to-Total-Asset is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ASKA Pharmaceutical Holdings Co stock overvalued right now?

Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,400.87, compared to a current price of 円2,259.00 — trading 5.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.07. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?

Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of 円2,259.00 is trading 5.9% below its estimated GF Value™ of 円2,400.87. GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.

Key valuation signals for TSE:4886:

LT-Debt-to-Total-Asset: 0.07
GF Value™: 円2,400.87 vs. price of 円2,259.00 (5.9% below fair value)
GF Score™: 61/100

No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ASKA Pharmaceutical Holdings Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSE:4569 TSE:4554 TSE:4577 TSE:4559 TSE:4595 TSE:9273 TSE:4538 TSE:2929 TSE:4574 TSE:4534 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address 2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532

Website https://www.aska-pharma-hd.co.jp

ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.

61GF Score

Get the complete analysis for TSE:4886

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,259.00

Price

円2,400.87

GF Value

View TSE:4886 Analysis

See LT-Debt-to-Total-Asset data for all stocks →